PPARG and metabolic dysfunction-associated steatohepatitis: Pioglitazone and Elafibranor, both Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) agonists, have advanced to Phase III clinical trials for the treatment of Non-Alcoholic Steatohepatitis (NASH), underscoring the relevance of PPAR-γ in fibrotic processes across various organs (Zhang et al., 2009).